Skip to main content
SpringerLink
Log in

Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials

  • Meta-Analysis
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

Given the increased risk of incident diabetes and the side effects on glycemic control with statin treatment, statin and ezetimibe combination therapy has been widely used. However, whether the same concern exists in ezetimibe remains uncertain. This meta-analysis aimed to investigate the influence of ezetimibe treatment on glycemic control.

Methods

Articles were searched from PubMed, EMBASE, and Cochrane Library. Randomized controlled trials (RCTs) were included if they compared the effects of ezetimibe with placebo, ezetimibe plus statin with the same statin, or low-dose stain plus ezetimibe with high-dose statin on FBG and glycosylated hemoglobin A1c (HbA1c).

Results

Of the 2440 articles retrieved, 16 RCTs were included. Ezetimibe did not cause side effects on FBG (WMD −0.62, 95% CI: −3.13 to 1.90) and HbA1c (WMD 0.07, 95% CI: −0.07 to 0.20%). No significant changes in FBG (WMD −1.78, 95% CI: −6.33 to 2.77%) and HbA1c (WMD −0.05, 95% CI: −0.14 to 0.05%) were observed in ezetimibe plus low-dose statin treatment compared with high-dose statin. According to subgroup analysis, in comparison with high-dose statin, ezetimibe plus low-dose statin taken for more than 3 months showed a significant decrease in FBG (WMD −7.12, 95% CI: −13.86 to −0.38%) compared with that taken for less than 3 months (WMD 0.90, 95% CI: −2.91 to 4.71%). Nevertheless, this difference was invalid when the study conducted by Dagli et al. was removed.

Conclusions

Compared with high-dose statin therapy, ezetimibe with low-dose statin for more than 3 months may have a beneficial tendency of effects on glycemic control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. C.J. Murray, A.D. Lopez, Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349(9061), 1269–1276 (1997). https://doi.org/10.1016/S0140-6736(96)07493-4

    Article  CAS  PubMed  Google Scholar 

  2. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, R. Simes; Cholesterol Treatment, C. Trialists, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005). https://doi.org/10.1016/S0140-6736(05)67394-1

    Article  CAS  PubMed  Google Scholar 

  3. Cholesterol Treatment Trialists, C., P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, R. Peto, J. Armitage, C. Baigent, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607), 117–125 (2008). https://doi.org/10.1016/S0140-6736(08)60104-X

    Article  Google Scholar 

  4. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, I. Ford, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716), 735–742 (2010). https://doi.org/10.1016/S0140-6736(09)61965-6

    Article  CAS  PubMed  Google Scholar 

  5. S. Erqou, C.C. Lee, A.I. Adler, Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia 57(12), 2444–2452 (2014). https://doi.org/10.1007/s00125-014-3374-x

    Article  CAS  PubMed  Google Scholar 

  6. E.A. Nutescu, N.L. Shapiro, Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 23(11), 1463–1474 (2003)

    Article  CAS  PubMed  Google Scholar 

  7. M. Garcia-Calvo, J. Lisnock, H.G. Bull, B.E. Hawes, D.A. Burnett, M.P. Braun, J.H. Crona, H.R. Davis Jr., D.C. Dean, P.A. Detmers, M.P. Graziano, M. Hughes, D.E. Macintyre, A. Ogawa, A. O’Neill K., S.P. Iyer, D.E. Shevell, M.M. Smith, Y.S. Tang, A.M. Makarewicz, F. Ujjainwalla, S.W. Altmann, K.T. Chapman, N.A. Thornberry, The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl Acad. Sci. USA 102(23), 8132–8137 (2005). https://doi.org/10.1073/pnas.0500269102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. M. Deushi, M. Nomura, A. Kawakami, M. Haraguchi, M. Ito, M. Okazaki, H. Ishii, M. Yoshida, Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 581(29), 5664–5670 (2007). https://doi.org/10.1016/j.febslet.2007.11.023

    Article  CAS  PubMed  Google Scholar 

  9. T. Muraoka, K. Aoki, T. Iwasaki, K. Shinoda, A. Nakamura, H. Aburatani, S. Mori, K. Tokuyama, N. Kubota, T. Kadowaki, Y. Terauchi, Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 60(5), 617–628 (2011). https://doi.org/10.1016/j.metabol.2010.06.008

    Article  CAS  PubMed  Google Scholar 

  10. Y. Nozaki, K. Fujita, M. Yoneda, K. Wada, Y. Shinohara, H. Takahashi, H. Kirikoshi, M. Inamori, K. Kubota, S. Saito, T. Mizoue, N. Masaki, Y. Nagashima, Y. Terauchi, A. Nakajima, Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J. Hepatol. 51(3), 548–556 (2009). https://doi.org/10.1016/j.jhep.2009.05.017

    Article  CAS  PubMed  Google Scholar 

  11. S. Hiramitsu, Y. Ishiguro, H. Matsuyama, K. Yamada, K. Kato, M. Noba, A. Uemura, S. Yoshida, Y. Matsubara, A. Kani, K. Hasegawa, H. Hishida, Y. Ozaki, The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J. Atheroscler. Thromb. 17(1), 106–114 (2010)

    Article  CAS  PubMed  Google Scholar 

  12. S. Yagi, M. Akaike, K. Aihara, T. Iwase, K. Ishikawa, S. Yoshida, Y. Sumitomo-Ueda, K. Kusunose, T. Niki, K. Yamaguchi, K. Koshiba, Y. Hirata, M. Dagvasumberel, Y. Taketani, N. Tomita, H. Yamada, T. Soeki, T. Wakatsuki, T. Matsumoto, M. Sata, Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J. Atheroscler. Thromb. 17(2), 173–180 (2010)

    Article  CAS  PubMed  Google Scholar 

  13. N. Dagli, M. Yavuzkir, I. Karaca, The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 30(6), 230–235 (2007). https://doi.org/10.1007/s10753-007-9041-3

    Article  CAS  PubMed  Google Scholar 

  14. N. Tamaki, H. Ueno, Y. Morinaga, T. Shiiya, M. Nakazato, Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J. Atheroscler. Thromb. 19(6), 532–538 (2012)

    Article  CAS  PubMed  Google Scholar 

  15. Y. Takeshita, T. Takamura, M. Honda, Y. Kita, Y. Zen, K. Kato, H. Misu, T. Ota, M. Nakamura, K. Yamada, H. Sunagozaka, K. Arai, T. Yamashita, E. Mizukoshi, S. Kaneko, The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 57(5), 878–890 (2014). https://doi.org/10.1007/s00125-013-3149-9

    Article  CAS  PubMed  Google Scholar 

  16. E. Moutzouri, E. Liberopoulos, D.P. Mikhailidis, M.S. Kostapanos, A.A. Kei, H. Milionis, M. Elisaf, Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int. J. Clin. Pract. 65(11), 1141–1148 (2011). https://doi.org/10.1111/j.1742-1241.2011.02779.x

    Article  CAS  PubMed  Google Scholar 

  17. K. Kikuchi, U. Nezu, K. Inazumi, T. Miyazaki, K. Ono, K. Orime, J. Shirakawa, K. Sato, H. Koike, T. Wakasugi, M. Sato, C. Kawakami, S. Watanabe, T. Yamakawa, Y. Terauchi, Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J. Atheroscler. Thromb. 19(12), 1093–1101 (2012)

    Article  CAS  PubMed  Google Scholar 

  18. M. Gonzalez-Ortiz, E. Martinez-Abundis, A.M. Kam-Ramos, E. Hernandez-Salazar, M.G. Ramos-Zavala, Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc. Drugs Ther. 20(2), 143–146 (2006). https://doi.org/10.1007/s10557-006-7805-x

    Article  CAS  PubMed  Google Scholar 

  19. M. Kishimoto, T. Sugiyama, K. Osame, D. Takarabe, M. Okamoto, M. Noda, Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. J. Med. Invest. 58(1-2), 86–94 (2011)

    Article  PubMed  Google Scholar 

  20. R. Cai, Y. Yuan, J. Sun, W. Xia, R. Huang, S. Tian, X. Dong, Y. Shen, S. Wang, Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis. Expert. Opin. Pharmacother. 17(14), 1839–1849 (2016). https://doi.org/10.1080/14656566.2016.1220539

    Article  CAS  PubMed  Google Scholar 

  21. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, J. Savovic, K.F. Schulz, L. Weeks, J.A. Sterne, G. Cochrane Bias Methods, Cochrane Statistical Methods, G.: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011). https://doi.org/10.1136/bmj.d5928

    Article  PubMed  PubMed Central  Google Scholar 

  22. J.P. Higgins, S. Green, Cochrane handbook for systematic reviews of interventions version 5.1.0. http://handbook.cochrane.org/

  23. K. Torimoto, Y. Okada, H. Mori, M. Hajime, K. Tanaka, A. Kurozumi, M. Narisawa, S. Yamamoto, T. Arao, H. Matsuoka, N. Inokuchi, Y. Tanaka, Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 12, 137 (2013). https://doi.org/10.1186/1476-511X-12-137

    Article  PubMed  PubMed Central  Google Scholar 

  24. I. Saito, K. Azuma, T. Kakikawa, N. Oshima, M.E. Hanson, A.M. Tershakovec, A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids Health Dis. 14, 40 (2015). https://doi.org/10.1186/s12944-015-0036-z

    Article  PubMed  PubMed Central  Google Scholar 

  25. D.C. Chan, G.F. Watts, S.K. Gan, E.M. Ooi, P.H. Barrett, Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 33(5), 1134–1139 (2010). https://doi.org/10.2337/dc09-1765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. K.J. Kim, S.H. Kim, Y.W. Yoon, S.W. Rha, S.J. Hong, C.H. Kwak, W. Kim, C.W. Nam, M.Y. Rhee, T.H. Park, T.J. Hong, S. Park, Y. Ahn, N. Lee, H.K. Jeon, D.W. Jeon, K.R. Han, K.W. Moon, I.H. Chae, H.S. Kim, Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc. Ther. 34(5), 371–382 (2016). https://doi.org/10.1111/1755-5922.12213

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. K. Winkler, S. Jacob, T. Muller-Schewe, M.M. Hoffmann, T. Konrad, Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis 220(1), 189–193 (2012). https://doi.org/10.1016/j.atherosclerosis.2011.10.043

    Article  CAS  PubMed  Google Scholar 

  28. P. Ruggenenti, D. Cattaneo, S. Rota, I. Iliev, A. Parvanova, O. Diadei, B. Ene-Iordache, S. Ferrari, A.C. Bossi, R. Trevisan, A. Belviso, G. Remuzzi, Ezetimibe, Simvastatin in Dyslipidemia of Diabetes Study, G.: Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care 33(9), 1954–1956 (2010). https://doi.org/10.2337/dc10-0320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. R. Krysiak, W. Zmuda, B. Okopien, The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. Cardiovasc. Ther. 32(2), 40–46 (2014). https://doi.org/10.1111/1755-5922.12057

    Article  CAS  PubMed  Google Scholar 

  30. G. Villegas-Rivera, L.M. Roman-Pintos, E.G. Cardona-Munoz, O. Arias-Carvajal, A.D. Rodriguez-Carrizalez, R. Troyo-Sanroman, F.P. Pacheco-Moises, A. Moreno-Ulloa, A.G. Miranda-Diaz, Effects of ezetimibe/simvastatin and rosuvastatin on oxidative stress in diabetic neuropathy: a randomized, double-blind, placebo-controlled clinical trial. Oxid. Med Cell Longev. 2015, 756294 (2015). https://doi.org/10.1155/2015/756294

    Article  PubMed  PubMed Central  Google Scholar 

  31. S.C. Ramos, F.A. Fonseca, S.H. Kasmas, F.T. Moreira, T. Helfenstein, N.C. Borges, R.A. Moreno, V.M. Rezende, F.C. Silva, M.C. Izar, The role of soluble fiber intake in patients under highly effective lipid-lowering therapy. Nutr. J. 10, 80 (2011). https://doi.org/10.1186/1475-2891-10-80

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Y. Kawagoe, Y. Hattori, A. Nakano, C. Aoki, S. Tanaka, S. Ohta, T. Iijima, A. Tomizawa, T. Jojima, H. Kase, K. Kasai, Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocr. J. 58(3), 171–175 (2011)

    Article  CAS  PubMed  Google Scholar 

  33. K. Sakamoto, M. Kawamura, T. Kohro, M. Omura, T. Watanabe, K. Ashidate, T. Horiuchi, H. Hara, N. Sekine, R. Chin, M. Tsujino, T. Hiyoshi, M. Tagami, A. Tanaka, Y. Mori, T. Inazawa, T. Hirano, T. Yamazaki, T. Shiba, R.S. Group, Effect of ezetimibe on LDL-C lowering and atherogenic lipoprotein profiles in type 2 diabetic patients poorly controlled by statins. PLoS ONE 10(9), e0138332 (2015). https://doi.org/10.1371/journal.pone.0138332

    Article  PubMed  PubMed Central  Google Scholar 

  34. W.L. Baker, R. Talati, C.M. White, C.I. Coleman, Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 87(1), 98–107 (2010). https://doi.org/10.1016/j.diabres.2009.10.008

    Article  CAS  PubMed  Google Scholar 

  35. S. Hiramitsu, K. Miyagishima, J. Ishii, S. Matsui, H. Naruse, K. Shiino, F. Kitagawa, Y. Ozaki, Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J. Cardiol. 60(5), 395–400 (2012). https://doi.org/10.1016/j.jjcc.2012.07.010

    Article  PubMed  Google Scholar 

  36. S. Ichimori, S. Shimoda, R. Goto, Y. Matsuo, T. Maeda, N. Furukawa, J. Kawashima, S. Kodama, T. Sekigami, S. Isami, K. Nishida, E. Araki, Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. J. Diabetes Investig. 3(2), 179–184 (2012). https://doi.org/10.1111/j.2040-1124.2011.00147.x

    Article  CAS  PubMed  Google Scholar 

  37. L. Bozzetto, G. Annuzzi, G.D. Corte, L. Patti, P. Cipriano, A. Mangione, G. Riccardi, A.A. Rivellese, Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 217(1), 142–148 (2011). https://doi.org/10.1016/j.atherosclerosis.2011.03.012

    Article  CAS  PubMed  Google Scholar 

  38. T. Tsunoda, T. Nozue, M. Yamada, I. Mizuguchi, M. Sasaki, I. Michishita, Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res. Clin. Pract. 100(1), 46–52 (2013). https://doi.org/10.1016/j.diabres.2012.12.026

    Article  CAS  PubMed  Google Scholar 

  39. A.Y. Her, J.Y. Kim, S.M. Kang, D. Choi, Y. Jang, N. Chung, I. Manabe, S.H. Lee, Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J. Cardiovasc. Pharmacol. Ther. 15(2), 167–174 (2010). https://doi.org/10.1177/1074248409357922

    Article  CAS  PubMed  Google Scholar 

  40. A.L. Kater, M.C. Batista, S.R. Ferreira, Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism 59(6), 921–926 (2010). https://doi.org/10.1016/j.metabol.2010.02.011

    Article  PubMed  Google Scholar 

  41. Y. Zhong, J. Wang, P. Gu, J. Shao, B. Lu, S. Jiang, Effect of ezetimibe on insulin secretion in db/db diabetic mice. Exp. Diabetes Res. 2012((), 420854 (2012). https://doi.org/10.1155/2012/420854

    PubMed  PubMed Central  Google Scholar 

  42. T. Nakamura, M. Hirano, Y. Kitta, D. Fujioka, Y. Saito, K. Kawabata, J.E. Obata, Y. Watanabe, K. Watanabe, K. Kugiyama, A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J. Cardiol. 60(1), 12–17 (2012). https://doi.org/10.1016/j.jjcc.2012.02.005

    Article  PubMed  Google Scholar 

  43. J.C. Sandoval, Y. Nakagawa-Toyama, D. Masuda, Y. Tochino, H. Nakaoka, R. Kawase, M. Yuasa-Kawase, K. Nakatani, M. Inagaki, K. Tsubakio-Yamamoto, T. Ohama, A. Matsuyama, M. Nishida, M. Ishigami, I. Komuro, S. Yamashita, Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J. Atheroscler. Thromb. 17(9), 914–924 (2010)

    Article  CAS  PubMed  Google Scholar 

  44. D. Masuda, Y. Nakagawa-Toyama, K. Nakatani, M. Inagaki, K. Tsubakio-Yamamoto, J.C. Sandoval, T. Ohama, M. Nishida, M. Ishigami, S. Yamashita, Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur. J. Clin. Invest. 39(8), 689–698 (2009). https://doi.org/10.1111/j.1365-2362.2009.02163.x

    Article  CAS  PubMed  Google Scholar 

  45. G. Boden, M. Laakso, Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 27(9), 2253–2259 (2004)

    Article  CAS  PubMed  Google Scholar 

  46. M. Bajaj, S. Suraamornkul, S. Kashyap, K. Cusi, L. Mandarino, R.A. DeFronzo, Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J. Clin. Endocrinol. Metab. 89(9), 4649–4655 (2004). https://doi.org/10.1210/jc.2004-0224

    Article  CAS  PubMed  Google Scholar 

  47. M. Nomura, H. Ishii, A. Kawakami, M. Yoshida, Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am. J. Physiol. Endocrinol. Metab. 297(5), E1030–E1038 (2009). https://doi.org/10.1152/ajpendo.00343.2009

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Second Affiliated Hospital of Mudanjiang Medical University, Mudanjiang, Heilongjiang, 157009, China

    Huijin Wu, Hua Shang & Jing Wu

Authors
  1. Huijin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hua Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Huijin Wu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, H., Shang, H. & Wu, J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine 60, 229–239 (2018). https://doi.org/10.1007/s12020-018-1541-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-018-1541-4

Keywords

Search

Navigation